Tresiba® (insulin degludec injection U-100) demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100
Geschrieben am 11-06-2016 |
New Orleans (ots/PRNewswire) -
This material is intended for global medical media only.
For
journalistic assessment and preparation before publication.
Abstracts 87-LB and 90-LB
New findings from the two phase 3b SWITCH trials showed that
treatment with long-acting basal insulin Tresiba® (insulin degludec
injection U-100) resulted in significantly lower rates of overall,
nocturnal and severe hypoglycaemia compared with insulin glargine
U-100.1,2 Results from the SWITCH 1 and 2 trials, the first completed
double-blinded basal insulin studies evaluating the safety profile
and efficacy of Tresiba® vs insulin glargine U-100,1,2 were presented
today at the American Diabetes Association 76th Scientific Sessions
in New Orleans, US.
In SWITCH 1, patients with type 1 diabetes taking Tresiba®
compared with insulin glargine U-100 experienced: a rate reduction of
11% in overall symptomatic blood glucose (BG) confirmed hypoglycaemic
episodes (95% confidence interval CI: 0.85; 0.94); a rate reduction
of 36% in nocturnal BG confirmed symptomatic hypoglycaemic episodes
(95% CI: 0.56; 0.73), and a rate reduction of 35% severe
hypoglycaemia (95% CI: 0.48; 0.89) during the maintenance period.1
All of the above analyses showed similar results in the full
treatment period.
In SWITCH 2, patients with type 2 diabetes taking Tresiba®
compared with insulin glargine U-100 experienced a rate reduction of
30% in overall BG confirmed symptomatic hypoglycaemic episodes (95%
CI: 0.61; 0.80) and a rate reduction of 42% in nocturnal BG confirmed
symptomatic hypoglycaemic episodes (95% CI: 0.46; 0.74). The above
analyses showed significant results in the full treatment period. In
the maintenance period, there was a trend towards lower rates of
severe hypoglycaemia in favour of Tresiba® vs insulin glargine U-100.
In the full treatment period, a significant 51% rate reduction in
severe hypoglycaemia was observed in patients receiving Tresiba® vs
insulin glargine U-100 (95% CI: 0.26; 0.94).2
"Hypoglycaemia is an ongoing challenge for people with type 1 and
type 2 diabetes," said Dr. Wendy Lane, lead SWITCH 1 study
investigator and clinical endocrinologist at Mountain Diabetes and
Endocrine Center in Asheville, N.C., U.S. "These findings are
important for the diabetes community, and add to the existing body of
evidence for Tresiba®."
Tresiba® (IDeg) was non-inferior to insulin glargine U-100 (IGlar
U-100) in reducing HbA1c in both treatment periods for both SWITCH 1
and 2 trials (SWITCH 1 treatment period 1: IDeg 6.92% vs IGlar U-100
6.78%; SWITCH 1 treatment period 2: IDeg 6.95% vs IGlar U-100 6.97%;
SWITCH 2 treatment period 1: IDeg 7.06% vs IGlar U-100 6.98%; SWITCH
2 treatment period 2: IDeg 7.08% vs IGlar U-100 7.11%).1-3 The
end-of-trial insulin doses were similar at the end of each treatment
period in both trials. The most common adverse events (>=5%) included
nasopharyngitis, upper respiratory tract infections and
hypoglycaemia.3-5
About SWITCH 1 and 2
The two phase 3b, 2x32-weeks randomised, double-blind, crossover,
treat-to-target trials were initiated in January 2014 to compare the
safety profile and efficacy of Tresiba® and insulin glargine U-100.
The overall objective was to document the hypoglycaemia profile in
type 1 diabetes and type 2 diabetes, respectively. During the
maintenance period, the primary endpoint studied was the number of
treatment emergent severe or BG confirmed symptomatic hypoglycaemic
episodes. The two secondary endpoints included: the number of
treatment emergent severe or BG confirmed nocturnal episodes and the
proportion of subjects with one or more severe hypoglycaemic
episodes. In SWITCH 1, 501 people with type 1 diabetes were
randomised to crossover treatment with Tresiba® and insulin glargine
U-100 in combination with insulin aspart. In SWITCH 2, 721 people
with type 2 diabetes were randomised to crossover treatment with
Tresiba® and insulin glargine U-100 in combination with oral
antidiabetic drugs.
About hypoglycaemia
Hypoglycaemia is a frequent complication in people with type 1 and
type 2 diabetes when low levels of blood glucose in the blood deprive
muscles, cells and the brain of the energy needed to function.6
Hypoglycaemia can be triggered by multiple factors including taking
too much insulin, not following the prescribed meal schedule or
participating in unusually strenuous or prolonged exercise.
About Tresiba®
Tresiba® (insulin degludec injection U-100) is a once-daily basal
insulin that provides a duration of action beyond 42 hours.7,8 It is
important for people with type 1 and type 2 diabetes to establish a
routine for insulin treatment. On occasions when administration at
the same time of day is not possible, Tresiba® allows for flexibility
in day-to-day dosing time when needed.7,9,10 Tresiba® received its
first regulatory approval in September 2012 and has since been
approved in more than 60 countries globally. It was most recently
approved by the FDA in the United States on 26 September 2015.
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90
years of innovation and leadership in diabetes care. This heritage
has given us experience and capabilities that also enable us to help
people defeat other serious chronic conditions: haemophilia, growth
disorders and obesity. Headquartered in Denmark, Novo Nordisk employs
approximately 41,600 people in 75 countries and markets its products
in more than 180 countries. For more information, visit
http://www.novonordisk.com,Facebook
(http://www.facebook.com/novonordisk), Twitter
(http://www.twitter.com/novonordisk), LinkedIn
(http://www.linkedin.com/company/novo-nordisk), YouTube
(http://www.Youtube.com/novonordisk).
Further information
Media:
Katrine Sperling
+45-4442-6718
krsp@novonordisk.com
Åsa Josefsson
+45-3079-7708
aajf@novonordisk.com
Michael Bachner
(US)
+1-609-664-7308
mzyb@novonordisk.com
Investors:
Peter Hugreffe Ankersen
+45-3075-9085
phak@novonordisk.com
Melanie Raouzeos
+45-3075-3479
mrz@novonordisk.com
Kasper Veje
(US)
+1-609-235-8567
kpvj@novonordisk.com
References
1. Lane W, Bailey T, Gerety G, et al. SWITCH 1: Reduced
Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine
(IGlar), both U100, in Patients With T1D at High Risk of
Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Abstract
87-LB presented at the 76th Annual Scientific Sessions of the
American Diabetes Association (ADA), New Orleans, USA. 11 June 2016.
2. Wysham C, Bhargava A, Chaykin L, et al. SWITCH 2: Reduced
Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine
(IGlar), both U100, in Patients With T2D at High Risk of
Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Abstract
90-LB presented at the 76th Annual Scientific Sessions of the
American Diabetes Association (ADA), New Orleans, USA. 11 June 2016.
3. Novo Nordisk. Data on file.
4. Lane W, Bailey T, Gerety G, et al. SWITCH 1: Reduced
Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine
(IGlar), both U100, in Patients With T1D at High Risk of
Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Poster
(#87-LB) presented at the 76th Annual Scientific Sessions of the
American Diabetes Association (ADA), New Orleans, USA. 11 June 2016.
5. Wysham C, Bhargava A, Chaykin L, et al. SWITCH 2: Reduced
Hypoglycaemia With Insulin Degludec (IDeg) vs Insulin Glargine
(IGlar), both U100, in Patients With T2D at High Risk of
Hypoglycaemia: A Randomised, Double-Blind Crossover Trial. Poster
(#90-LB) presented at the 76th Annual Scientific Sessions of the
American Diabetes Association (ADA), New Orleans, USA; 11 June 2016.
6. Willis WD, Diago-Cabezudo JI, Madec-Hily A, et al. Medical
resource use, disturbance of daily life and burden of hypoglycemia in
insulin-treated patients with diabetes: results from a European
online survey. Expert Review of Pharmacoeconomics & Outcomes
Research. 2013; 13:123-30.
7. EMA. Tresiba® summary of product characteristics. Available
at:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Produc
t_Information/human/002498/WC500138940.pdf Last accessed: June 2016.
8. Haahr H, Heise T. A review of the pharmacological properties
of insulin degludec and their clinical relevance. Clinical
Pharmacokinetics. 2014; 53:787-800.
9. Meneghini L, Atkin SL, Gough SC, et al. The efficacy and
safety of insulin degludec given in variable once-daily dosing
intervals compared with insulin glargine and insulin degludec dosed
at the same time daily: a 26-week, randomized, open-label,
parallel-group, treat-to-target trial in individuals with type 2
diabetes. Diabetes Care. 2013; 36:858-864.
10. Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy
and safety of insulin degludec in a flexible dosing regimen vs
insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a
26-week randomized, treat-to-target trial with a 26-week extension.
The Journal of Clinical Endocrinology & Metabolism. 2013;
98:1154-1162.
ots Originaltext: Novo Nordisk A/S
Im Internet recherchierbar: http://www.presseportal.de
Kontaktinformationen:
Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.
Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.
Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.
http://www.bankkaufmann.com/topics.html
Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.
@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf
E-Mail: media(at)at-symbol.de
592858
weitere Artikel:
- BDI vor China-Reise der Bundeskanzlerin: "Industrie will tiefere Integration Chinas in die Weltwirtschaft" Berlin (ots) -
- Für weitergehenden Schutz vor Dumping
- China muss Überkapazitäten abbauen
Der Bundesverband der Deutschen Industrie (BDI) will eine tiefere
Integration Chinas in die Weltwirtschaft. "Geltendes Recht und damit
auch Chinas Beitrittsprotokoll zur Welthandelsorganisation WTO haben
absoluten Vorrang. Ziel muss sein, bei der Vergabe des
Marktwirtschaftsstatus an China eine langfristig tragfähige Lösung zu
finden, die den Schutz der deutschen und europäischen Industrie vor
gedumpten Waren aus China garantiert." mehr...
- Nutzung digitaler Werbemaßnahmen steigt weiter Köln (ots) - Digital oder analog - Die Mehrheit der befragten
Unternehmen setzt auf einen Marketingmix. Dabei steigt die Nutzung
digitaler Werbemaßnahmen: Besonders Social Media (plus 13 %) und
Online-Werbemaßnahmen (plus 5 %) wuchsen in den vergangenen zwei
Jahren. Die Skepsis gegenüber Mobile Marketing bleibt hoch. Das zeigt
eine repräsentative Umfrage im Auftrag von Greven Medien.
Eine eigene Website ist mittlerweile für 81 % aller befragten
Unternehmen Standard. Schon 56 % haben ihre Website für mobile
Endgeräte optimiert. mehr...
- taz: taz-Kommentar von Svenja Bergt über Dumpingpreise für Lebensmittel Berlin (ots) - Was muss passieren, damit Schweinehalter jubeln?
Frühlingshafte Temperaturen plus Fußballmeisterschaft. Ergibt:
Grillwetter und steigende Nachfrage nach Schweinefleisch. Ganze 1,50
Euro bekommen die Erzeuger derzeit pro Kilo - 26 Cent mehr als noch
im Februar.
Wenn es um niedrige Preise für Lebensmittel geht, stehen immer
zwei Probleme im Fokus: der absurd niedrige Milchpreis und mit ihm
die armen, unter den niedrigen Preisen leidenden Milchbauern. Das ist
nicht falsch, aber unvollständig: Schließlich sind es in mehr...
- Semaglutide Demonstrated Superior Improvements in Glycaemic Control vs Sitagliptin (SUSTAIN 2) and Exenatide ER (SUSTAIN 3) in Two Clinical Trials in Adults With Type 2 Diabetes New Orleans (ots/PRNewswire) -
This material is intended for global medical media only.
For journalistic assessment and preparation before publication.
Abstracts 185-OR and 187-OR
Findings from two phase 3a clinical trials for semaglutide, an
investigational glucagon-like peptide-1 (GLP-1) analogue, were
presented today at the American Diabetes Association 76th Scientific
Sessions.[1],[2] In the SUSTAIN 2 trial, 0.5 mg and 1.0 mg
semaglutide administered once-weekly significantly improved glycaemic
control compared mehr...
- MCM X Christopher Ræburn bei der London Collections Men Frühjahr/Sommer 2017 London (ots/PRNewswire) -
MCM und der aufstrebende britische Designer Christopher Raeburn
präsentierten anlässlich des diesjährigen 40. Geburtstags des
deutschen Luxuslabels eine gemeinsame Capsule Collection für die
Frühjahr/Sommer 2017 Saison. Die beiden Marken zeigen eine
Reinterpretation des Begriffs "Movement" und stellen
verantwortungsbewusste und nachhaltige Kreativität kühn dar. Die
Kollektion, die am 11. Juni 2016 als Teil der London Collections Men
vorgestellt wurde, definiert modernes Reisen für globale Nomaden mit mehr...
|
|
|
Mehr zu dem Thema Aktuelle Wirtschaftsnews
Der meistgelesene Artikel zu dem Thema:
DBV löst Berechtigungsscheine von knapp 344 Mio. EUR ein
durchschnittliche Punktzahl: 0 Stimmen: 0
|